1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Active Pharmaceutical Ingredients Global Market – Forecast To 2020

Active Pharmaceutical Ingredients Global Market – Forecast To 2020

  • November 2014
  • -
  • IQ4I Research & Consultancy Pvt. Ltd
  • -
  • 282 pages

The global active pharmaceutical ingredient market is expected to reach approximately $175 billion by 2020, growing at a CAGR of around 6% during forecast period. Active pharmaceutical ingredient is any substance or mixture of substances used in a finished pharmaceutical product with pharmacological activity used for diagnosis, cure, mitigation, treatment and prevention of diseases. Very less number of finished pharmaceutical product manufacturers has their own API manufacturing unit and nobody can make all required APIs in-house. It is basically not easy for API manufacturers in developing countries to ensure a product with quality at a reasonable price. API manufacturing involves conversion of raw materials into API and mixing API and excipients for final formulations. These formulations in the form of tablets, capsules or solutions are packaged and then marketed.

Patent expiration of major drugs that increased generic drug sales, government initiatives, increasing aged population and regional penetration, local manufacturer expansion and high uptake of biologics are some of the factors that are driving the market growth. Whereas financial crisis, stringent regulatory policies, less investment in pharmaceutical industry and fragmented market are the factors that are hindering API market growth.
The global API market is segmented based on synthesis, customer base, business type and therapeutic applications. Depending on synthesis the market is classified into synthetic chemical API, biotech API and HPAPI (Highly Potent Active Pharmaceutical Ingredient). Biotech API is further segmented into mammalian cell culture, monoclonal antibodies, recombinant proteins, vaccines, insulin analog, growth hormones and interferons. Mammalian cell culture accounted for the largest share in 2013, while monoclonal antibody segment is the fastest growing segment by 2020. Despite low production yields, high manufacturing cost and highly unstable cell culturing method mammalian culture is the largest due to post-translational mechanism present in living cells. Monoclonal antibodies are growing at a faster pace due to demand for biotech APIs and increasing venture capital investments that drives the market.

By-customer base the API market is segmented into synthetic chemicals API, biotech API and HPAPI. Synthetic chemical API is further classified into branded/innovative and generic/non-branded API. Branded API accounted for the largest share whereas, generic is the fastest growing segment. Biotech API is further divided into biologics and biosimilars where biologics accounted for the largest share.

Depending on business type the API market is segmented into captive and merchant. Captive market accounted for the largest revenue in 2013. Based on the therapeutic applications the global API market is categorized into eleven crucial application areas such as anti-infectives, oncology, cardiovascular and hematopoietic system, central nervous system, gastrointestinal disorder, respiratory system, hormonal-related disorder, metabolic disorder, genito-urinary disorder, musculo-skeletal disorder and others. Anti-infectives segment dominated the application market with a largest in 2013 whereas oncology segment is the fastest growing segment with a CAGR of approximately 8% by 2020. Patent expiration of major drugs, increased incidence of various cancer diseases and aged population, high government investments for cancer research and healthcare awareness are the factors that drives the market whereas stringent regulations, failure of crucial drugs in last stage of clinical trial, and economical crisis are the factors that hampers the market growth.

Geographically API market is segmented into North America, Asia-Pacific, Europe and Rest of the world regions. North America dominated the global API market during the forecast period. Asia Pacific region is the fastest growing with a CAGR of more than 7.5% by 2020 due to patent expirations of drugs, low operation costs, services of Contract Manufacturing Organizations (CMO) and high investments in medical research. Moreover the high cost of skilled labor and energy are the major factors that forced European market to shift their base to countries such as India and China.

Major players in the API market include Teva Active Pharmaceutical Industries Limited (Israel), Ranbaxy Laboratories (India), Dr. Reddy's Lab (India), Boehringer Ingelheim GmbH (Germany), Lonza group (Switzerland), Lupin (India), Novartis (Switzerland), Aurobindo pharma (India), and Albemarle Corporation (U.S.).

Table Of Contents

Active Pharmaceutical Ingredients Global Market - Forecast To 2020
1 EXECUTIVE SUMMARY 192
INTRODUCTION 23
2.1 KEY TAKE AWAYS 23
2.2 REPORT DESCRIPTION 23
2.3 MARKETS COVERED 25
2.4 STAKEHOLDERS 26
2.5 RESEARCH METHODOLOGY 27
2.5.1 MARKET SIZE ESTIMATION 28
2.5.2 MARKET CRACK DOWN and DATA TRIANGULATION 31
2.5.3 SECONDARY RESEARCH RESOURCES 32
2.5.4 PRIMARY RESEARCH RESOURCES 33
2.5.5 ASSUMPTIONS 33
3 MARKET ANALYSIS 34
3.1 INTRODUCTION 34
3.2 MARKET SEGMENTATION 35
3.3 FACTORS INFLUENCING MARKET 37
3.3.1 DRIVERS AND OPPORTUNITIES 38
3.3.1.1 Patent expiration of major drugs that increased generic medicine sales 38
3.3.1.2 Government initiation for biomedical research 39
3.3.1.3 High uptake of biologics across diverse therapeutic areas 40
3.3.1.4 Increasing regional penetration and aged population 40
3.3.1.5 Increasing mergers and acquisitions 42
3.3.1.6 Expansion of local manufacturers 42
3.3.2 RESTRAINTS AND THREATS 43
3.3.2.1 Financial crisis 43
3.3.2.2 Stringent regulatory policies 43
3.3.2.3 Less investment for API manufacturing companies 44
3.3.2.4 High market fragmentation and genericization of branded drugs 44
3.3.3 BURNING ISSUES 45
3.3.3.1 Contamination in formulation and bulk drugs 45
3.3.4 WINNING IMPERATIVE 46
3.3.4.1 Low cost labor market 46
3.3.5 MARKET TRENDS 46
3.4 REGULATORY AFFAIRS 48
3.4.1 U.S. 48
3.4.2 EUROPE 48
3.4.3 ASIA PACIFIC 49
3.4.4 REST OF THE WORLD 50
3.5 PORTER'S FIVE FORCE ANALYSIS 50
3.5.1 THREAT OF NEW ENTRANTS 51
3.5.2 THREAT OF SUBSTITUTES 52
3.5.3 BARGAINING POWER OF BUYERS 52
3.5.4 BARGAINING POWER OF SUPPLIERS 52
3.5.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS 53
3.6 SUPPLY CHAIN ANALYSIS 53
3.7 MARKET SHARE ANALYSIS 55
4 GLOBAL API MARKET OVERVIEW 57
4.1 BY SYNTHESIS 57
4.1.1 SYNTHETIC CHEMICALS API 60
4.1.2 BIOTECH API 63
4.1.2.1 Introduction 63
4.1.2.2 Mammalian cell culture 67
4.1.2.3 Monoclonal antibodies 68
4.1.2.4 Recombinant proteins 71
4.1.2.5 Vaccines 72
4.1.2.6 Insulin analog 74
4.1.2.7 Growth hormones 76
4.1.2.8 Interferons 78
4.1.3 HPAPI 79
4.2 BY CUSTOMER BASE 81
4.2.1 SYNTHETIC CHEMICALS 83
4.2.1.1 Branded/innovative synthetic chemicals 83
4.2.1.2 Generic/non- branded synthetic chemicals 85
4.2.2 BIOTECH API 86
4.2.2.1 Biologics 87
4.2.2.2 Biosimilars 89
4.2.3 HPAPI 91
4.3 BY BUSINESS TYPE 94
4.3.1 CAPTIVE 95
4.3.2 MERCHANT 97
5 GLOBAL API MARKET, BY THERAPEUTIC APPLICATION 100
5.1 INTRODUCTION 100
5.2 ANTI-INFECTIVES 102
5.3 ONCOLOGY 105
5.4 CARDIOVASCULAR DISEASES 106
5.5 CENTRAL NERVOUS SYSTEM 109
5.6 RESPIRATORY SYSTEM 110
5.7 GASTROINTESTINAL 112
5.8 HORMONE-RELATED DISORDERS 113
5.9 METABOLIC DISORDERS 115
5.9.1 DIABETES 115
5.9.2 OBESITY 116
5.10 GENITOURINARY DISORDERS 118
5.11 MUSCULOSKELETAL DISORDERS 120
5.12 OTHERS 122
5.12.1 ANESTHESIA 122
5.12.2 EYE 122
5.12.3 ENT (EAR NOSE THROAT) DISORDERS 123
6 REGIONAL MARKET ANALYSIS 125
6.1 INTRODUCTION 125
6.2 NORTH AMERICA 127
6.3 EUROPE 136
6.4 ASIA PACIFIC 145
6.5 REST OF THE WORLD 156
7 COMPANY DEVELOPMENTS 164
7.1 INTRODUCTION 164
7.1.1 PRODUCT APPROVALS AS A MAJOR GROWTH STRATEGY OF ACTIVE PHARMACEUTICAL INGREDIENTS MARKET PLAYERS 164
7.2 APPROVAL 166
7.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS and JOINT VENTURES 178
7.4 NEW PRODUCT LAUNCH 182
7.5 MERGERS AND ACQUISITIONS 185
7.6 OTHER DEVELOPMENTS 187
8 MAJOR PLAYER PROFILES 189
8.1 ALBEMARLE CORPORATION 189
8.1.1 OVERVIEW 189
8.1.2 FINANCIALS 190
8.1.3 PRODUCT PORTFOLIO 191
8.1.4 KEY DEVELOPMENTS 192
8.1.5 BUSINESS STRATEGY 193
8.1.6 SWOT ANALYSIS 194
8.2 AUROBINDO PHARMA LIMITED 195
8.2.1 OVERVIEW 195
8.2.2 FINANCIALS 196
8.2.3 PRODUCT PORTFOLIO 197
8.2.4 KEY DEVELOPMENTS 204
8.2.5 BUSINESS STRATEGY 207
8.2.6 SWOT ANALYSIS 207
8.3 BOEHRINGER INGELHEIM GMBH 208
8.3.1 OVERVIEW 208
8.3.2 FINANCIALS 209
8.3.3 PRODUCT PORTFOLIO 210
8.3.4 KEY DEVELOPMENTS 212
8.3.5 BUSINESS STRATEGY 214
8.3.6 SWOT ANALYSIS 215
8.4 DR. REDDY'S LABORATORIES LIMITED 216
8.4.1 OVERVIEW 216
8.4.2 FINANCIALS 217
8.4.3 PRODUCT PORTFOLIO 218
8.4.4 KEY DEVELOPMENTS 224
8.4.5 BUSINESS STRATEGY 227
8.4.6 SWOT ANALYSIS 228
8.5 FRESENIUS KABI 229
8.5.1 OVERVIEW 229
8.5.2 FINANCIALS 230
8.5.3 PRODUCT PORTFOLIO 232
8.5.4 KEY DEVELOPMENTS 233
8.5.5 BUSINESS STRATEGY 234
8.5.6 SWOT ANALYSIS 234
8.6 LONZA GROUP LTD 235
8.6.1 OVERVIEW 235
8.6.2 FINANCIALS 236
8.6.3 PRODUCT PORTFOLIO 237
8.6.4 KEY DEVELOPMENTS 239
8.6.5 BUSINESS STRATEGY 240
8.6.6 SWOT ANALYSIS 241
8.7 LUPIN LIMITED 242
8.7.1 OVERVIEW 242
8.7.2 FINANCIALS 243
8.7.3 PRODUCT PORTFOLIO 244
8.7.4 KEY DEVELOPMENTS 246
8.7.5 BUSINESS STRATEGY 247
8.7.6 SWOT ANALYSIS 248
8.8 NOVARTIS INTERNATIONAL AG 249
8.8.1 OVERVIEW 249
8.8.2 FINANCIALS 250
8.8.3 PRODUCT PORTFOLIO 251
8.8.4 KEY DEVELOPMENTS 254
8.8.5 BUSINESS STRATEGY 255
8.8.6 SWOT ANALYSIS 256
8.9 RANBAXY LABORATORIES LIMITED 257
8.9.1 OVERVIEW 257
8.9.2 FINANCIALS 258
8.9.3 PRODUCT PORTFOLIO 259
8.9.4 KEY DEVELOPMENTS 262
8.9.5 BUSINESS STRATEGY 263
8.9.6 SWOT ANALYSIS 264
8.10 SUN PHARMACEUTICALS INDUSTRIES LTD 265
8.10.1 OVERVIEW 265
8.10.2 FINANCIALS 266
8.10.3 PRODUCT PORTFOLIO 267
8.10.4 KEY DEVELOPMENTS 272
8.10.5 BUSINESS STRATEGY 274
8.10.6 SWOT ANALYSIS 274
8.11 TEVA ACTIVE PHARMACEUTICAL INGREDIENTS 275
8.11.1 OVERVIEW 275
8.11.2 FINANCIALS 276
8.11.3 PRODUCT PORTFOLIO 277
8.11.4 KEY DEVELOPMENTS 278
8.11.5 BUSINESS STRATEGY 280
8.11.6 SWOT ANALYSIS 281

LIST OF TABLES

TABLE 1 API MARKET REVENUE, BY REGION, (2012-2020) ($BN) 21
TABLE 2 API MARKET, GLOBAL MARKET REVENUE, BY SYNTHESIS (2012-2020) ($BN) 58
TABLE 3 SYNTHETIC CHEMICALS API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 61
TABLE 4 SYNTHETIC CHEMICALS GLOBAL API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS, (2012-2020) ($BN) 62
TABLE 5 BIOTECH API GLOBAL MARKET REVENUE, BY TYPE (2012-2020) ($BN) 65
TABLE 6 BIOTECH API GLOBAL MARKET REVENUE, BY THERAPEUTIC APPLICATIONS, (2012-2020) ($BN) 66
TABLE 7 MAMMALIAN CELL CULTURE BIOTECH API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 68
TABLE 8 MONOCLONAL ANTIBODIES BIOTECH API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 70
TABLE 9 RECOMBINANT PROTEINS BIOTECH API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 72
TABLE 10 VACCINES BIOTECH API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 74
TABLE 11 INSULIN ANALOG BIOTECH API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 76
TABLE 12 GROWTH HORMONES BIOTECH API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 77
TABLE 13 INTERFERONS BIOTECH API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 79
TABLE 14 HPAPI GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 81
TABLE 15 SYNTHETIC CHEMICALS API GLOBAL MARKET REVENUE, BY CUSTOMER BASE (2012-2020) ($BN) 83
TABLE 16 BRANDED/INNOVATIVE SYNTHETIC CHEMICALS API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 84
TABLE 17 GENERIC/NON-BRANDED SYNTHETIC CHEMICALS API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 86
TABLE 18 BIOTECH API GLOBAL MARKET REVENUE, BY CUSTOMER BASE (2012-2020) ($BN) 87
TABLE 19 BIOLOGICS BIOTECH API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 89
TABLE 20 BIOSIMILARS BIOTECH API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 91
TABLE 21 HPAPI GLOBAL MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2012-2020) ($BN) 93
TABLE 22 API GLOBAL MARKET REVENUE, BY BUSINESS TYPE (2012-2020) ($BN) 94
TABLE 23 CAPTIVE API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 97
TABLE 24 MERCHANT API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 99
TABLE 25 API GLOBAL MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2012-2020) ($BN) 101
TABLE 26 ANTI-INFECTIVES API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 105
TABLE 27 ONCOLOGY API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 106
TABLE 28 CARDIOVASCULAR AND HEMATOPOIETIC SYSTEM API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 108
TABLE 29 CENTRAL NERVOUS SYSTEM API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 110
TABLE 30 RESPIRATORY SYSTEM API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 112
TABLE 31 GASTROINTESTINAL API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BNN) 113
TABLE 32 HORMONAL RELATED DISORDERS API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 115
TABLE 33 METABOLIC DISORDERS API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 118
TABLE 34 GENITO-URINARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 119
TABLE 35 MUSCULO-SKELETAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 121
TABLE 36 OTHERS API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 124
TABLE 37 API GLOBAL MARKET REVENUE, BY REGION (2012-2020) ($BN) 125
TABLE 38 NORTH AMERICAN API MARKET REVENUE, BY SYNTHESIS, (2012-2020) ($BN) 128
TABLE 39 NORTH AMERICAN BIOTECH API MARKET REVENUE, BY TYPE (2012-2020) ($BN) 129
TABLE 40 NORTH AMERICAN SYNTHETIC CHEMICALS API GLOBAL MARKET REVENUE, BY CUSTOMER BASE (2012-2020) ($BN) 130
TABLE 41 NORTH AMERICAN BIOTECH API GLOBAL MARKET REVENUE, BY CUSTOMER BASE (2012-2020) ($BN) 130
TABLE 42 NORTH AMERICAN API MARKET REVENUE, BY BUSINESS TYPE (2012-2020) ($BN) 131
TABLE 43 NORTH AMERICAN API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2012-2020) ($BN) 132
TABLE 44 NORTH AMERICAN SYNTHETIC CHEMICALS API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2012-2020) ($BN) 133
TABLE 45 NORTH AMERICAN BIOTECH API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2012-2020) ($BN) 134
TABLE 46 NORTH AMERICAN HPAPI MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2012-2020) ($BN) 135
TABLE 47 EUROPEAN API MARKET REVENUE, BY SYNTHESIS (2012-2020) ($BN) 137
TABLE 48 EUROPEAN BIOTECH API MARKET REVENUE, BY TYPE (2012-2020) ($BN) 138
TABLE 49 EUROPEAN SYNTHETIC CHEMICALS API GLOBAL MARKET REVENUE, BY CUSTOMER BASE (2012-2020) ($BN) 139
TABLE 50 EUROPEAN BIOTECH API GLOBAL MARKET REVENUE, BY CUSTOMER BASE (2012-2020) ($BN) 139
TABLE 51 EUROPEAN API MARKET REVENUE, BY BUSINESS TYPE (2012-2020) ($BN) 140
TABLE 52 EUROPEAN API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2012-2020) ($BN) 141
TABLE 53 EUROPEAN SYNTHETIC CHEMICALS API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2012-2020) ($BN) 142
TABLE 54 EUROPEAN BIOTECH API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS, (2012-2020) ($BN) 143
TABLE 55 EUROPEAN HPAPI MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2012-2020) ($BN) 144
TABLE 56 ASIA-PACIFIC API MARKET REVENUE, BY SYNTHESIS (2012-2020) ($BN) 146
TABLE 57 ASIA-PACIFIC BIOTECH API MARKET REVENUE, BY TYPE (2012-2020) ($BN) 146
TABLE 58 ASIA-PACIFIC SYNTHETIC CHEMICALS API GLOBAL MARKET REVENUE, BY CUSTOMER BASE (2012-2020) ($BN) 147
TABLE 59 ASIA-PACIFIC BIOTECH API GLOBAL MARKET REVENUE, BY CUSTOMER BASE (2012-2020) ($BN) 148
TABLE 60 ASIA-PACIFIC API MARKET REVENUE, BY BUSINESS TYPE (2012-2020) ($BN) 148
TABLE 61 ASIA-PACIFIC API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2012-2020) ($BN) 149
TABLE 62 ASIA-PACIFIC SYNTHETIC CHEMICALS API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2012-2020) ($BN) 150
TABLE 63 ASIA-PACIFIC BIOTECH API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2012-2020) ($BN) 151
TABLE 64 ASIA-PACIFIC HPAPI MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2012-2020) ($BN) 152
TABLE 65 ROW API MARKET REVENUE, BY SYNTHESIS (2012-2020) ($BN) 157
TABLE 66 ROW BIOTECH API MARKET REVENUE, BY TYPE (2012-2020) ($BN) 157
TABLE 67 ROW SYNTHETIC CHEMICALS API GLOBAL MARKET REVENUE, BY CUSTOMER BASE (2012-2020) ($BN) 158
TABLE 68 ROW BIOTECH API GLOBAL MARKET REVENUE, BY CUSTOMER BASE (2012-2020) ($BN) 159
TABLE 69 ROW API MARKET REVENUE, BY BUSINESS TYPE (2012-2020) ($BN) 159
TABLE 70 ROW API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2012-2020) ($BN) 160
TABLE 71 ROW SYNTHETIC CHEMICALS API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2012-2020) ($BN) 161
TABLE 72 ROW BIOTECH API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2012-2020) ($BN) 162
TABLE 73 ROW HPAPI MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2012-2020) ($BN) 163
TABLE 74 APPROVALS (2012-2014) 166
TABLE 75 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS and JOINT VENTURES (2012-2014) 178
TABLE 76 NEW PRODUCT LAUNCHES (2012-2014) 182
TABLE 77 MERGERS AND ACQUISITIONS (2012-2014) 185
TABLE 78 OTHER DEVELOPMENTS (2012-2014) 187
TABLE 79 ALBEMARLE CORPORATION.: TOTAL REVENUE AND RandD EXPENSES (2011-2013) ($BN) 190
TABLE 80 ALBEMARLE CORPORATION.: TOTAL REVENUE, BY SEGMENTS (2011-2013) ($BN) 190
TABLE 81 ALBEMARLE CORPORATION.: TOTAL REVENUE, BY GEOGRAPHY (2011-2013) ($BN) 191
TABLE 82 AUROBINDO PHARMA LIMITED: TOTAL REVENUE AND RandD EXPENSES (2011-13) ($BN) 196
TABLE 83 AUROBINDO PHARMA LIMITED: TOTAL REVENUE, BY SEGMENT (2011-13) ($BN) 196
TABLE 84 AUROBINDO PHARMA LIMITED: TOTAL REVENUE, BY GEOGRAPHY (2011-13) ($BN) 197
TABLE 85 BOEHRINGER INGELHEIM GMBH: TOTAL REVENUE AND RandD EXPENSES (2011-2013) ($BN) 209
TABLE 86 BOEHRINGER INGELHEIM GMBH TOTAL REVENUE, BY SEGMENTS (2011-2013) ($BN) 209
TABLE 87 BOEHRINGER INGELHEIM GMBH TOTAL REVENUE, BY GEOGRAPHY (2011-2013) ($BN) 210
TABLE 88 DR. REDDY'S LABORATORIES LIMITED: TOTAL REVENUE AND RandD EXPENSES (2011-13) ($BN) 217
TABLE 89 DR. REDDY'S LABORATORIES LIMITED: TOTAL REVENUE, BY SEGMENT (2011-13) ($BN) 217
TABLE 90 DR. REDDY'S LABORATORIES LIMITED: TOTAL REVENUE, BY GEOGRAPHY (2011-13) ($BN) 218
TABLE 91 FRESENIUS KABI.: TOTAL REVENUE AND RandD EXPENSES (2011-2013) ($BN) 230
TABLE 92 FRESENIUS KABI.: TOTAL REVENUE, BY BUSINESS SEGMENTS (2011-2013) ($BN) 230
TABLE 93 FRESENIUS KABI.: TOTAL REVENUE, BY SEGMENTS (2011-2013) ($BN) 231
TABLE 94 FRESENIUS KABI TOTAL REVENUE, BY GEOGRAPHY (2011-2013) ($BN) 231
TABLE 95 LONZA GROUP LTD TOTAL REVENUE AND RandD EXPENSES (2011-2013) ($BN) 236
TABLE 96 LONZA GROUP LTD TOTAL REVENUE, BY SEGMENTS (2011-2013) ($BN) 236
TABLE 97 LONZA GROUP LTD TOTAL REVENUE, BY GEOGRAPHY (2011-2013) ($BN) 237
TABLE 98 LUPIN LIMITED: TOTAL REVENUE AND RandD EXPENSES (2011-13) ($BN) 243
TABLE 99 LUPIN LIMITED: TOTAL REVENUE, BY SEGMENT (2011-13) ($BN) 243
TABLE 100 LUPIN LIMITED: TOTAL REVENUE, BY GEOGRAPHY (2011-13) ($BN) 244
TABLE 101 NOVARTIS INTERNATIONAL AG.: TOTAL REVENUE AND RandD EXPENSES (2011-2013) ($MN) 250
TABLE 102 NOVARTIS INTERNATIONAL AG.: TOTAL REVENUE, BY SEGMENTS (2011-2013) ($MN) 250
TABLE 103 NOVARTIS INTERNATIONAL AG.: TOTAL REVENUE, BY GEOGRAPHY (2011-2013) ($MN) 251
TABLE 104 RANBAXY LABORATORIES LIMITED.: TOTAL REVENUE AND R and D EXPENSES (2011-2013) ($BN) 258
TABLE 105 RANBAXY LABORATORIES LIMITED.: TOTAL REVENUE, BY SEGMENTS (2011-2013) ($BN) 258
TABLE 106 RANBAXY LABORATORIES LIMITED.: TOTAL REVENUE, BY GEOGRAPHY (2011-2013) ($BN) 259
TABLE 107 SUN PHARMACEUTICALS INDUSTRIES LTD: TOTAL REVENUE AND RandD EXPENSES (2011-2013) ($BN) 266
TABLE 108 SUN PHARMACEUTICALS INDUSTRIES LTD: TOTAL REVENUE, BY SEGMENTS (2011-2013) ($BN) 266
TABLE 109 SUN PHARMACEUTICALS INDUSTRIES LTD: TOTAL REVENUE, BY GEOGRAPHY (2011-2013) ($BN) 267
TABLE 110 TEVA ACTIVE PHARMACEUTICAL INGREDIENT.: TOTAL REVENUE AND RandD EXPENSES (2011-2013) ($MN) 276
TABLE 111 TEVA ACTIVE PHARMACEUTICAL INGREDIENT.: TOTAL REVENUE, BY SEGMENTS (2011-2013) ($MN) 276
TABLE 112 TEVA ACTIVE PHARMACEUTICAL INGREDIENT.: TOTAL REVENUE, BY GEOGRAPHY (2011-2013) ($MN) 277

























LIST OF FIGURES

FIGURE 1 GLOBAL API MARKET SHARE, BY REGION (2013) 22
FIGURE 2 RESEARCH METHODOLOGY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET 28
FIGURE 3 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: TOP-DOWN AND BOTTOM-UP APPROACH 29
FIGURE 4 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: FORECASTING MODEL 30
FIGURE 5 API MARKET: MARKET CRACKDOWN and DATA TRIANGULATION 31
FIGURE 6 GLOBAL API MARKET: MARKET SEGMENTATION 36
FIGURE 7 MARKET DYNAMICS 37
FIGURE 8 API MARKET: PORTER'S ANALYSIS 51
FIGURE 9 API MARKET: SUPPLY CHAIN ANALYSIS 54
FIGURE 10 GLOBAL API MARKET SHARE ANALYSIS BY KEY PLAYER, 2013 55
FIGURE 11 GLOBAL API MARKET REVENUE, BY SYNTHESIS TYPE (2013 V'S 2020) ($BN) 59
FIGURE 12 GLOBAL BIOTECH API MARKET SHARE, BY SYNTHESIS TYPE (2013 V'S 2020) 64
FIGURE 13 GLOBAL SYNTHETIC CHEMICALS API MARKET SHARE, BY CUSTOMER BASE (2013 V'S 2020) 82
FIGURE 14 GLOBAL API MARKET REVENUE, BY BUSINESS TYPE (2012 - 2020) 95
FIGURE 15 GLOBAL API MARKET SHARE, BY THERAPEUTIC APPLICATIONS (2013) ($BN) 102
FIGURE 16 GLOBAL API MARKET SNAPSHOT, BY MAJOR MARKETS (2012 - 2020) 126
FIGURE 17 GLOBAL API MARKET SCENARIO, BY REGION (2012 - 2020) ($BN) 127
FIGURE 18 API EMERGING REGIONS MARKET SNAPSHOT, BY MANUFACTURER BASE (2013) 145
FIGURE 19 KEY GROWTH STRATEGIES, (2012-2014) 165
FIGURE 20 SWOT: ALBEMARLE CORPORATION 194
FIGURE 21 SWOT ANALYSIS: AUROBINDO PHARMA LIMITED 207
FIGURE 22 SWOT: BOEHRINGER INGELHEIM GMBH 215
FIGURE 23 SWOT ANALYSIS: DR. REDDY'S LABORATORIES LIMITED 228
FIGURE 24 SWOT: FRESENIUS KABI 234
FIGURE 25 SWOT: LONZA GROUP LTD 241
FIGURE 26 SWOT ANALYSIS: LUPIN LIMITED 248
FIGURE 27 SWOT.: NOVARTIS INTERNATIONAL AG 256
FIGURE 28 SWOT: RANBAXY LABORATORIES LIMITED 264
FIGURE 29 SWOT: SUN PHARMACEUTICALS INDUSTRIES LTD 274
FIGURE 30 SWOT: TEVA ACTIVE PHARMACEUTICAL INGREDIENT 281

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.